Using RT-PCR and Sanger sequencing, the fusion gene CRYL1-IFT88 was successfully validated in the discovery sequencing sample (P10 tumor sample) and it was also validated in another 5 tumor samples (Figures 1, 2). Here, CRYL1 is linked to neoplasm.